Duvelisib

Fact of Medicine
Brand Name: Copiktra
Innovator Brand Name: Copiktra
API: Duvelisib
Packaging: 14/28/56 Capsules
Strength: 15/25mg
Manufacturer Name: Verastem, Inc.

Get Price

Description

Duvelisib of Medication:

Copiktra (Duvelisib) is a kinase inhibitor used for the treatment of adult patients with: relapsed/refractory CLL or SLL after at least 2 earlier therapies. relapsed/refractory FL following at least 2 earlier systemic therapies.

Dosage: The recommended dosage is duvelisib 25 mg administered as oral capsules twice in a day with/without food. A cycle consists of 28 days. The capsules of duvelisib should be swallowed whole. Patients are advised to not open, break, or chew the capsules. Patients are advised that if a dose is missed by fewer than six hours, to administer the missed dose promptly and administer the next dose as usual. And if a duvelisib dose is missed by over six hours, patients are advised to wait and administer the next dose at about the usual time.

Side Effects: The most commonly reported duvelisib side effects may include:

  • Diarrhea or Colitis
  • Neutropenia
  • Rash
  • Fatigue
  • Pyrexia
  • Cough
  • Nausea
  • Anemia
  • Upper respiratory infection
  • Pneumonia
  • Musculoskeletal pain

Warnings and Precautions:

Patients taking treatment with copiktra 25 mg are advised to report any new or worsening diarrhea. Patients with duvelisib therapy are advised of the need for periodic monitoring of blood counts. Patients should be monitored for the hepatic function during therapy with copiktra capsules. Females should inform their doctor if they are pregnant or become pregnant. Use of duvelisib 15 mg during pregnancy may be hazardous to the fetus.

More info

Storage: Store Duvelisib at 20° to 25°C (68° to 77°F), with excursions permitted at 15° to 30°C (59° to 86°F). Retain the original package until the time of dispensing. Dispense blister packs of duvelisib in the original container. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship COPIKTRA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the COPIKTRA Capsules. Buying Procedure: In order to buy COPIKTRA, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919650877511 or an Email to us at: info@theindianpharma.com along with your Identity Proof, Legitimate Prescription Letter and Medical Reports. Conclusion: The FDA approval of Copiktra (duvelisib capsules), an oral PI3K inhibitor, offers a breakthrough treatment option as a monotherapy for relapsed/refractory CLL or SLL and relapsed or refractory FL (Follicular Lymphoma). The clinical trial findings on duvelisib showed significant efficacy benefits, and also an acceptable safety profile.

FAQ

What is Copiktra? Copiktra is a prescription medication used for treating adults with CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma), and Follicular Lymphoma (FL). What does Copiktra contain as an active substance? The medication Copiktra specifically contains the active substance Duvelisib. What are the different strengths of Duvelisib? It is available in the two different strength as capsule form: ● duvelisib 15 mg ● duvelisib 25 mg Is Duvelisib an FDA approved drug? Yes, Duvelisib is an FDA approved drug. How much does copiktra cost? The copiktra price in India usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price of Duvelisib? Please contact Toll-free: +91 1800 889 1064|+919650877511 for duvelisib price in India. We take guarantee of quality as well as delivery anywhere in the world as per the buyer’s requirements. Can I get Copiktra (Duvelisib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Copiktra (Duvelisib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Reviews

There are no reviews yet.

Be the first to review “Duvelisib”

Your email address will not be published.

×